MiniMed to Showcase MiniMed Flex™ and MiniMed Go™ at the American Diabetes Association Scientific Sessions

MiniMed (Nasdaq: MMED) will showcase its new MiniMed Flex™ pump and recently launched MiniMed Go™ smart insulin pen at the American Diabetes Association Scientific Sessions in New Orleans, June 5-8, 2026.

Rhea-AI Summary

MiniMed (Nasdaq: MMED) will showcase its new MiniMed Flex™ pump and recently launched MiniMed Go™ smart insulin pen at the American Diabetes Association Scientific Sessions in New Orleans, June 5-8, 2026.

MiniMed will offer hands-on demos, sponsored symposia, and multiple poster presentations on MiniMed™ 780G and Instinct™ sensor real-world and clinical outcomes.

Argus May 27 session

-3.40% close to close Open Argus

Details

News Market Reaction – MMED

On May 27, the day this news came out, MMED closed 3.40% below the previous close.

Data tracked by StockTitan Argus for the May 27 session.

Key Figures

ADA dates: June 5-8 Product theater time: 12:30-1:30 p.m. CT Learning byte time: 11:00-11:20 a.m. CT +5 more

ADA dates

June 5-8

American Diabetes Association Scientific Sessions in New Orleans

Product theater time

12:30-1:30 p.m. CT

MiniMed product theater on Saturday, June 6

Learning byte time

11:00-11:20 a.m. CT

“Better days and nights with MiniMed” session on Sunday, June 7

Exhibit booth

Booth #1406

Main MiniMed exhibit at ADA Scientific Sessions

Learning byte booth

Booth #927

Location for MiniMed learning byte in Exhibition Hall

Instinct sensor duration

15-day

Duration of new Instinct sensor in randomized controlled study

Simplera Sync duration

7-day

Wear duration of Simplera Sync sensor comparator

Meals analyzed

over 389,796 meals

Real-world analysis of bolusing and postprandial control in MiniMed 780G users

Historical Context

5 past events · Latest: May 26

5 events

1. May 26

   Conference participation

   24h Move

   -5.8%

   Announcement of participation in Goldman Sachs healthcare conference.

2. May 21

   Clinical outcomes data

   24h Move

   +0.8%

   Trial and real-world data showing strong MiniMed 780G glycemic outcomes.

3. Apr 13

   Earnings date set

   24h Move

   +5.7%

   Scheduling of Q4 and full-year 2026 earnings release and webcast.

4. Mar 18

   FDA clearance

   24h Move

   -0.2%

   FDA clearance of MiniMed Flex™, a smaller smartphone-controlled insulin pump.

5. Mar 09

   IPO completion

   24h Move

   +1.8%

   Closing of IPO and start of Nasdaq trading, raising new capital.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

automated insulin delivery, glycemic outcomes, c-peptide, randomized controlled study, +4 more

8 terms

automated insulin delivery medical

""Expanding the Use of Automated Insulin Delivery in Puerto Rico, from Type 1 to Type 2 Diabetes""

A system that links a glucose sensor, an insulin pump, and control software so insulin is adjusted automatically to keep blood sugar near a target range, similar to a smart thermostat that regulates room temperature. It matters to investors because it replaces manual dosing with continuous, data-driven care, which can drive device sales, recurring subscription software services, better health outcomes, and regulatory interest—factors that affect market growth and company valuation.

glycemic outcomes medical

""Three-Year Sustainability of Glycemic Outcomes in Latin American Users of the MiniMed™ 780G System""

Glycemic outcomes are the measurable results showing how well a treatment, device or lifestyle change controls blood sugar levels over time, using metrics such as average blood glucose, fluctuations and episodes of low blood sugar. Investors care because these results indicate a product’s effectiveness, safety and potential to gain regulatory approval, reimbursement and market adoption—think of it as a thermostat reading that shows whether a solution keeps a room (blood sugar) in a healthy range.

c-peptide medical

""Glycemic Benefits with the MiniMed™ 780G System are Observed Across a Range of C-peptide Levels in People with Type 2 Diabetes""

C‑peptide is a short protein fragment released at the same time the pancreas produces insulin; because it lingers in the blood longer than insulin itself, clinicians measure C‑peptide levels as a clear sign of how much natural insulin a person still makes. For investors, C‑peptide matters because it’s used as a measurable outcome in diabetes drug and device trials, in diagnostic tests, and by regulators to judge treatment benefit — results that can affect clinical success, approvals, and market value.

randomized controlled study medical

""Performance of the New 15-day Instinct Sensor ... - A Randomized Controlled Study""

A randomized controlled study assigns participants by chance into two or more groups — one that gets the thing being tested and one that does not — so outcomes can be compared fairly. Like flipping a coin to decide who tries a new lightbulb in a neighborhood, this method reduces bias and helps investors judge whether a treatment, product, or strategy truly works and how reliably, which affects forecasts, regulatory decisions, and market value.

postprandial medical

""The Impact of On-Time and Late Bolusing on Postprandial Glycaemic Control in MiniMed 780G System Users""

Postprandial describes the period after a person has eaten, usually referring to changes in the body such as blood sugar, blood lipid levels, or drug absorption that occur in the hours following a meal. For investors, postprandial measures matter because many medical tests, diabetes treatments, weight-loss drugs, and nutritional products are evaluated by how they perform after eating; think of it as checking how a car runs once it's been refueled.

euglycemia medical

""MiniMed™ 780G Delivers Morning Euglycemia Regardless of Bedtime Glucose Levels""

Euglycemia is the state of having blood sugar (glucose) levels within a healthy, normal range. Investors watch this term because achieving or maintaining euglycemia is a key goal for diabetes drugs, medical devices and treatments; like a thermostat keeping room temperature stable, treatments that reliably produce euglycemia indicate effectiveness and lower risk of costly complications, which can affect a product’s market value and adoption.

in silico medical

""In Silico Development and Clinical Validation of a Full Closed-Loop (FCL) Algorithm""

In silico means using computer models, simulations, or data analysis to study biological, chemical, or financial processes instead of physical experiments. For investors, in silico work can speed up research, lower costs and highlight promising opportunities or risks early—like using a flight simulator to test maneuvers before flying a real plane—while still requiring real-world testing to confirm results.

closed-loop medical

""In Silico Development and Clinical Validation of a Full Closed-Loop (FCL) Algorithm""

A closed-loop system automatically measures its own output and feeds that information back to adjust inputs, operating without the need for constant human intervention — like a thermostat that senses room temperature and turns the heater on or off to keep a set point. Investors pay attention because closed-loop products often deliver more consistent performance, lower operational costs, and stronger regulatory or competitive advantages, which can improve revenue prospects, margins and risk profiles for companies that make or use them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Following this week's launch of MiniMed Go™, MiniMed will bring hands-on demonstrations of the system and new clinical data

NORTHRIDGE, Calif., May 27, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced an overview of its upcoming presence at the American Diabetes Association's (ADA) Scientific Sessions in New Orleans June 5-8. The meeting marks MiniMed's first U.S. diabetes congress since becoming a standalone public company — and the first to feature its newest generation of technology designed to give people with diabetes more freedom every day.

At ADA, MiniMed will showcase technology designed to reduce the daily burden of diabetes while delivering strong clinical outcomes. From advanced automation to smaller, more intuitive designs, the company continues to focus on one simple idea: to make every day a better day for people with diabetes.

In addition to its latest innovations, MiniMed will present emerging clinical data demonstrating the real-world impact of its connected solutions, including the impact of its recently refreshed sensor portfolio.

Attendees will also have hands-on opportunities to explore the highly anticipated MiniMed Flex™ system, a next-generation screenless, smartphone-controlled pump with real-time SmartGuard™ automation, and MiniMed Go™, the smart insulin pen system that remembers, reminds and recommends.

MiniMed Sponsored Events
The following symposia will feature discussions with MiniMed and independent speakers. Details are as follows:

Product Theater titled "MiniMed: Introducing new insulin delivery systems" will showcase the MiniMed Go™ and MiniMed Flex™ systems, on Saturday, June 6, 12:30-1:30 p.m. CT in Theater B, featuring Anuj Bhargava, MD, MBA, CDCES, FACP, FACE CEO & Medical Director Iowa Diabetes and Johan Jendle, MD PhD Professor of Medicine Institute of Medical Sciences, Örebro University, Director for the Diabetes Endocrinology and Metabolism Research Center.

Learning Byte titled "Better days and nights with MiniMed" by Robert Vigersky, MD, Vice President and Chief Medical Officer, MiniMed, on Sunday, June 7 at 11:00-11:20 a.m. CT, Exhibition Hall at Booth #927.

Exhibit (Booth #1406) featuring interactive components focused on diabetes technology, clinical outcomes and support offerings for HCPs and patients, including a showcase of our product pipeline with the MiniMed Go™ and MiniMed Flex™ system.

Scientific Presentations
The following poster presentations showcase the work of MiniMed employees and independent investigators using MiniMed devices in their research. Posters will be on display in the Poster Hall and attendees can view them throughout the conference.

• "Expanding the Use of Automated Insulin Delivery in Puerto Rico, from Type 1 to Type 2 Diabetes" – poster (1856-P) by Matias Castro, Principal Medical Science Liaison Specialist, MiniMed, LATAM & Canada, on Saturday, June 6, 12:30-1:30 p.m. CT.
• "Three-Year Sustainability of Glycemic Outcomes in Latin American Users of the MiniMed™ 780G System" – poster (1857-P) by Matias Castro, Principal Medical Science Liaison Specialist, MiniMed, LATAM & Canada, on Saturday, June 6, 12:30-1:30 p.m. CT.
• "MiniMed™ 780G System Users with Spanish Or English Language Settings Achieve Similar Glycemic Outcomes" – poster (1854-P) by Jessica Cardin, MS, RD, LD/N, Diabetes Evidence Strategy Manager, MiniMed, on Saturday, June 6, 12:30-1:30 p.m. CT.
• "Sustained Glycemic Outcomes with Reduction in Burden: MiniMed™ 780G System Outcomes are Met and Sustained in Children over a 3-year Period" – poster (1855-P) by Jessica Cardin, MS, RD, LD/N, Diabetes Evidence Strategy Manager, MiniMed, on Saturday, June 6, 12:30-1:30 p.m. CT.
• "Medicaid Beneficiaries with Type 1 and Type 2 Diabetes Achieve ADA-Recommended Glycemic Targets Using the MiniMed™ 780G System" – poster (1862-P) by Jennifer McVean, MD, Sr. Medical Director, MiniMed, on Saturday, June 6, 12:30-1:30 p.m. CT.
• "Medicare Beneficiaries with Type 1 and Type 2 Diabetes Using the MiniMed™ 780G System Exceed Glycemic Targets" – poster (1863-P) by Jennifer McVean, MD, Sr. Medical Director, MiniMed, on Saturday, June 6, 12:30-1:30 p.m. CT.
• "Glycemic Benefits with the MiniMed™ 780G System are Observed Across a Range of C-peptide Levels in People with Type 2 Diabetes (PwT2D)" – poster (1866-P) by Anders Carlson, MD, International Diabetes Center, on Saturday, June 6, 12:30-1:30 p.m. CT.
• "Real-World Performance of the MiniMed™780G Advanced Hybrid Closed-loop System with the Newly Introduced Instinct™ Sensor in the United States" – poster (1891-P) by John J. Shin, PhD, MBA, Sr. Clinical Research Director, MiniMed, on Saturday, June 6, 12:30-1:30 p.m. CT.
• "Successful and Safe Updates by Firmware Over-the-Air of Software Systems and Interchanging Continuous Glucose Sensors of the MiniMed 780G System" – poster (1870-P) by Ohad Cohen, MD, Sr. Medical Affairs Director, MiniMed, and Amir Tirosh, MD, Associate Professor of Medicine, School of Medicine, Tel-Aviv University, on Saturday, June 6, 12:30-1:30 p.m. CT.
• "Performance of the New 15-day Instinct Sensor Compared to the 7-day Simplera Sync™ Sensor when used with the MiniMed™ 780G System- A Randomized Controlled Study" – poster (1894-P) by Ohad Cohen, MD, Sr. Medical Affairs Director, MiniMed, and Amir Tirosh, MD, Associate Professor of Medicine, School of Medicine, Tel-Aviv University, on Saturday, June 6, 12:30-1:30 p.m. CT.
• "The Impact of On-Time and Late Bolusing on Postprandial Glycaemic Control in MiniMed 780G System Users: A Real-World Analysis of Over 389,796 Meals" – poster (2885-LB) by John J. Shin, PhD, MBA, Sr. Clinical Research Director, MiniMed, on Sunday, June 7, 12:30-1:30 p.m. CT.
• "MiniMed™ 780G Delivers Morning Euglycemia Regardless of Bedtime Glucose Levels" – poster (2882-LB) by Matias Castro, Principal Medical Science Liaison Specialist, MiniMed, LATAM & Canada, on Sunday, June 7, 12:30-1:30 p.m. CT.
• "In Silico Development and Clinical Validation of a Full Closed-Loop (FCL) Algorithm" – poster (2883-LB) by Benyamin Grosman, PhD, Sr. Distinguished Scientist, MiniMed, on Sunday, June 7, 12:30-1:30 p.m. CT.
• "Reduced Burden and Maintained Glycemic Control with MiniMed™ 780G System Recommended Optimal Settings in Users Who Do Not Employ Optional Sensor Glucose (SG) Alerts" –poster (2886-LB) by Toni L. Cordero, PhD, BCMAS, Sr. Medical Science Writing Program Manager, MiniMed, on Sunday, June 7, 12:30-1:30 p.m. CT.

About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.

Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-to-showcase-minimed-flex-and-minimed-go-at-the-american-diabetes-association-scientific-sessions-302782655.html

SOURCE MiniMed

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is MiniMed presenting at the 2026 ADA Scientific Sessions for MMED shareholders?

MiniMed is presenting its MiniMed Flex™ pump, MiniMed Go™ smart insulin pen, and new MiniMed™ 780G and Instinct™ sensor data. According to MiniMed, attendees can experience hands-on demos, product theater events, and numerous scientific posters highlighting real-world and clinical outcomes.

What is the MiniMed Flex™ system that MiniMed (MMED) will showcase at ADA 2026?

MiniMed Flex™ is a next-generation, screenless, smartphone-controlled insulin pump featuring real-time SmartGuard™ automation. According to MiniMed, it is designed to reduce daily diabetes burden through advanced automation, smaller form factor, and intuitive operation demonstrated during hands-on sessions at the ADA Scientific Sessions.

What is the MiniMed Go™ smart insulin pen system highlighted by MiniMed (MMED)?

MiniMed Go™ is a smart insulin pen system that remembers, reminds, and recommends insulin dosing support. According to MiniMed, it is part of a connected ecosystem aimed at easing day-to-day diabetes management and will be featured in product theaters and booth demonstrations at ADA 2026.

Which MiniMed™ 780G clinical and real-world studies are featured at ADA 2026?

MiniMed-sponsored and independent posters cover MiniMed™ 780G use in Puerto Rico, Latin America, Medicaid and Medicare populations, and across C-peptide ranges. According to MiniMed, additional analyses assess bolusing behavior, morning euglycemia, firmware updates, and Instinct™ versus Simplera Sync™ sensors in randomized and real-world settings.

When and where can clinicians see MiniMed (MMED) presentations at the 2026 ADA meeting?

Key MiniMed activities run June 5-8, 2026, in New Orleans, including a June 6 product theater and June 7 learning byte. According to MiniMed, interactive exhibits are located at Booth #1406, with posters displayed in the conference Poster Hall.

How do MiniMed’s Instinct™ and Simplera Sync™ sensors feature in MMED data at ADA 2026?

MiniMed highlights a randomized controlled study comparing the 15-day Instinct™ sensor with the 7-day Simplera Sync™ sensor when used with MiniMed™ 780G. According to MiniMed, additional posters describe real-world performance of the 780G system paired with the newly introduced Instinct™ sensor in the United States.